IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn’s Disease: A Meta-analysis of Randomized Controlled Trials

By sjmartinez • March 13, 2025

Dziegielewski C, Yuan Y, Ma C, Boland BS, Chang JT, Syal G, Vuyyuru SK, Peyrin-Biroulet L, Jairath V, Singh S. IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials. Am J Gastroenterol. 2025 Mar 12. doi: 10.14309/ajg.0000000000003406. Epub ahead of print. PMID: 40071763.

Tags: Digestive Diseases, Publications

Related Posts

Radiology considerations for the PREMIUM study: a multicenter randomized controlled trial of abbreviated MRI versus ultrasound for liver cancer screening in cirrhosis

Dunn DP, Dani G, Sharma A, Ioannou GN, Taddei TH, Chang ST, Onyiuke IY, Planeta BM, Huang GD, Weiss NS, Morgan TR, Dominitz JA, Abou-Alfa[...]

Effect of Age and Age-Defined Menopausal Status on Linaclotide Efficacy and Safety in Adults With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation: Post Hoc Analyses of Phase 2b/3 Studies

Chang L, Staller K, Houghton LA, Yerneni N, Higgins S, Chen W, Wu J, Ford AC, Feuerstadt P, Brenner DM. Effect of Age and Age-Defined[...]

Psychotherapy vs antidepressants in heart failure: Impact of adherence

IsHak WW, Hamilton MA, Diniz MA, Mirocha J, Chernoff R, Hedrick R, Aronow H, Darwish T, Messineo G, Pasini M, Olanisa L, Tetrault E, Arun[...]